Less than a year after CordenPharma earmarked a major chunk of change to beef up in peptide manufacturing for GLP-1s and ...

At the time of my last article in April, VKTX reported data from a study of four weeks treatment with oral VK2735 in obese subjects, but only up to 40 mg (3.7% placebo-adjusted weight loss).

Viking Therapeutics (VKTX) announced that it has signed a broad, multi-year manufacturing agreement with CordenPharma, a contract development ...

It is developing VK2735, an investigational novel dual GLP-1 and GIP receptor agonist, in different clinical studies as oral and subcutaneous (SC) formulations for treating obesity. The rumors of ...

Concurrently, the company is evaluating an oral formulation of VK2735 in a Phase 1 trial. Viking is also developing VK2809, a novel, orally available, small molecule selective thyroid hormone ...